Arthrex Inc, a major US orthopaedic company finalized the license of our tibial fixation implant, and gained FDA approval and a CE mark (https://www.arthrex.com/innovations/index.cfm?adid=44), before placing the device on the market as GraftBolt®. Patent protection was progressing in a number of territories (Europe, US, Canada and Australia) and, with less than a year of sales in 2010, the license generated nearly $76,000 for the NHS and the University to share. It was expecting the GraftBolt sales about $2,000,000 only in USA in 2011.
|Effective start/end date||1/03/10 → 1/03/11|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.